Encompass Health Corporation (NYSE:EHC) Stock Now Rated “Buy” by Wall Street Analysts

Encompass Health Corporation (NYSE:EHC – Get Free Report) has been assigned a consensus recommendation of “Buy” from the eight research firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $154.25.

EHC has been the subject of a number of recent research reports. UBS Group increased their price objective on Encompass Health from $155.00 to $165.00 and gave the company a “buy” rating in a report on Friday, October 30th. Wall Street Zen raised Encompass Health from a “hold” rating to a “buy” rating in a report on Saturday, October 31st. TD Cowen lifted their target price on Encompass Health from $140.00 to $150.00 and gave the stock a “buy” rating in a report on Friday, October 30th. KeyCorp upped their price target on Encompass Health from $147.00 to $150.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Finally, Weiss Ratings raised Encompass Health from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th.

Read Our Latest Report on Encompass Health

Encompass Health Trading Down 1.1%

Shares of Encompass Health stock opened at $140.67 on Friday. The firm’s 50 day moving average is $126.33 and its 200 day moving average is $111.79. The firm has a market capitalization of $13.80 billion, a PE ratio of 21.98, a price-to-earnings-growth ratio of 2.47 and a beta of 0.83. Encompass Health has a 1 year low of $92.77 and a 1 year high of $143.90. The company has a current ratio of 1.09, a quick ratio of 1.09 and a debt-to-equity ratio of 0.73.

Encompass Health (NYSE:EHC – Get Free Report) last issued its quarterly earnings data on Wednesday, October 28th. The company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.36 by $0.16. Encompass Health had a net margin of 10.17% and a return on equity of 18.35%. The business had revenue of $1.61 billion during the quarter, compared to the consensus estimate of $1.60 billion. During the same quarter in the prior year, the firm earned $1.23 EPS. The firm’s revenue was up 8.9% compared to the same quarter last year. Equities research analysts forecast that Encompass Health will post 6.29 earnings per share for the current fiscal year.

Encompass Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 15th. Stockholders of record on Monday, January 4th will be given a $0.21 dividend. The ex-dividend date of this dividend is Monday, January 4th. This represents a $0.84 annualized dividend and a dividend yield of 0.6%. Encompass Health’s dividend payout ratio (DPR) is 13.12%.

Insider Transactions at Encompass Health

In related news, EVP John Darby sold 4,858 shares of the business’s stock in a transaction on Monday, August 31st. The shares were sold at an average price of $121.09, for a total transaction of $588,255.22. Following the transaction, the executive vice president owned 75,041 shares in the company, valued at $9,086,714.69. The trade was a 6.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.80% of the company’s stock.

Institutional Trading of Encompass Health

Several hedge funds have recently bought and sold shares of EHC. Benjamin Edwards Inc. boosted its stake in shares of Encompass Health by 1.9% in the 3rd quarter. Benjamin Edwards Inc. now owns 9,293 shares of the company’s stock valued at $1,129,000 after purchasing an additional 175 shares in the last quarter. First Trust Advisors LP grew its holdings in shares of Encompass Health by 3.1% during the 3rd quarter. First Trust Advisors LP now owns 322,432 shares of the company’s stock valued at $39,172,000 after purchasing an additional 9,655 shares during the last quarter. Allianz SE purchased a new position in Encompass Health in the 3rd quarter worth $184,000. Whittier Trust Co. raised its position in Encompass Health by 57.5% in the 3rd quarter. Whittier Trust Co. now owns 638 shares of the company’s stock worth $79,000 after purchasing an additional 233 shares during the period. Finally, Advisors Asset Management Inc. bought a new stake in Encompass Health in the third quarter worth $557,000. Institutional investors and hedge funds own 97.25% of the company’s stock.

Encompass Health Company Profile

(Get Free Report)

Encompass Health Corporation is a U.S. healthcare provider focused on inpatient rehabilitation. The company operates rehabilitation hospitals that offer specialized care for people recovering from conditions such as strokes, brain and spinal cord injuries, orthopedic conditions, and other illnesses or injuries. Its hospitals provide coordinated rehabilitation services, including physical, occupational, and speech therapy, alongside medical care. Encompass Health serves patients through facilities across the United States.

Further Reading

Analyst Recommendations for Encompass Health (NYSE:EHC)

Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.